Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2005 | 12-2004 | |
| Sales | 1,180 | 3,738 |
| Cost of Goods | 481 | 198 |
| Gross Profit | 699 | 3,540 |
| Operating Expenses | 31,121 | 28,132 |
| Operating Income | -29,941 | -24,393 |
| Interest Expense | 225 | 133 |
| Other Income | 1,174 | 501 |
| Pre-tax Income | -28,992 | -24,025 |
| Net Income Continuous | -28,992 | -24,025 |
| Net Income | $-28,992 | $-24,025 |
| EPS Basic Total Ops | -241,511.40 | -309,132.70 |
| EPS Basic Continuous Ops | -174,054.80 | -172,560.90 |
| EPS Diluted Total Ops | -241,511.40 | -309,132.70 |
| EPS Diluted Continuous Ops | -174,054.80 | -172,560.90 |
| EBITDA(a) | $-29,138 | $-23,627 |